Drug Trial Radar · NCT07287189
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Mar 31, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Satellos Bioscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years, up to 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.
Conditions
- Duchenne Muscular Dystrophy
- Duchenne
- DMD
- Neuromuscular Diseases
- Muscular Dystrophies
Interventions
SAT-3247Drug
SAT-3247 is a selective AAK1 inhibitor for oral tablet administration which promotes functional rescue of asymmetric satellite cell division, resulting in the robust production of muscle progenitor cells, subsequent improvement in muscle regeneration, and enhanced muscle function.
PlaceboDrug
matching placebo oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of SAT-3247Time frame: 12 weeks in Part 1 and up to 12 months in part 2
- Tolerability of SAT-3247Time frame: 12 weeks in Part 1 and up to 12 months in Part 2
- SAT-3247 effects on muscle strengthTime frame: 12 weeks in Part 1 and up to 12 months in Part 2
Locations
20 sites in 8 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Colorado Children's
Aurora, Colorado
Lurie Children's
Chicago, Illinois
UMass Memorial Medical Center
Worcester, Massachusetts
Washington University
St Louis, Missouri
Nationwide Children's Hospital
Columbus, Ohio
Seattle Children's
Seattle, Washington
Children's Hospital at Westmead
Westmead, New South Wales, Australia
Royal Children's Hospital Melbourne
Melbourne, Victoria, Australia
Hôpital De La Citadelle (CHR)
Liège, Liège, Belgium
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Children's Hospital Eastern Ontario
Ottawa, Ontario, Canada
Instytut Centrum Zdrowia Matki Polki
Lodz, Łódź Voivodeship, Poland
Klinika Neurologii Rozwojowej Uniwersyteckie
Gdansk, Pomeranian Voivodeship, Poland
University Children's Clinic Tirsova
Belgrade, Serbia, Serbia
Mother and Child Health Care Institute
Belgrade, Serbia, Serbia
Hospital Infantil i Hospital de la Dona
Barcelona, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Basque Country, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Valencia, Spain
Great Ormond Street
London, UK, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.